KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Pooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections. PMID 40913503 · Infect Dis (Lond) · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Perfluorohexyloctane Eye Drops in Premenopausal and Postmenopausal Women with Dry Eye Disease Associated with Meibomian Gland Dysfunction: A Post Hoc Analysis of a Phase 3 Trial. PMID 40898391 · Curr Eye Res · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First-in-Human Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Phase 1 Study. PMID 40884306 · Clin Pharmacol Drug Dev · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double-Blind, Placebo-Controlled Study. PMID 40884302 · Clin Pharmacol Drug Dev · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial. PMID 40876598 · Ophthalmology · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bioequivalence and Food Effect Assessment of Apalutamide Tablets Relative to Erleada in Healthy Chinese Male Participants. PMID 40862641 · Clin Pharmacol Drug Dev · 2026-Jan The record is a randomized, open-label, single-dose, crossover bioequivalence study of apalutamide in healthy volunteers. It does not meet the required criteria for a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The study focuses on pharmacokinetic parameters, not cancer treatment efficacy. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of patient-reported outcomes in patients achieving complete versus near-complete skin clearance following Vunakizumab treatment: a post-hoc analysis of a phase III trial. PMID 40853464 · Naunyn Schmiedebergs Arch Pharmacol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Geographical Distribution of Phase II/III Pharmaceutical Randomized Controlled Trials in Adults With Interstitial Lung Disease. PMID 40818774 · Chest · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Randomized Sham-Controlled Phase 2/3 Trial of QPI-1007 for Acute Nonarteritic Anterior Ischemic Optic Neuropathy. PMID 40816607 · Ophthalmology · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma. PMID 40803577 · J Hepatol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment. PMID 40793974 · Aliment Pharmacol Ther · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Reassessing survival outcomes: a closer look at the randomized trial on minimally invasive surgery for endometrial cancer. PMID 40783119 · Am J Obstet Gynecol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan. PMID 40771035 · Mov Disord Clin Pract · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Randomized Trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms: DSETAMIS-2018 Study. PMID 40749854 · Gastroenterology · 2026-Jan The study is an oncology randomized trial with original results, but it does not meet key eligibility criteria: it is not explicitly a Phase III trial, it does not involve a drug-containing intervention (both are surgical/endoscopic procedures), and the primary endpoint (12-month recurrence) is not reported as a time-to-event analysis with Kaplan-Meier curves or hazard ratios.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ovarian stimulation with follitropin delta is safe and effective: results from the RITA randomized, double-blind, placebo-controlled trials. PMID 40714031 · Fertil Steril · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A clinical study of ten-year prognosis in patients with lumbar disc herniation treated with condoliase in a phase III trial. PMID 40664535 · J Orthop Sci · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation: An Early Remission Induction Study. PMID 40524500 · Arthritis Rheumatol · 2026-Jan The study is a Phase III trial of golimumab (a drug intervention) in human patients with axial spondyloarthritis, which is an inflammatory disease, not a malignant neoplasm (cancer). Therefore, it fails the core oncology eligibility criterion. Additionally, the trial is not randomized (it is a single-arm, open-label study) and the primary efficacy endpoint is not a time-to-event endpoint (it reports the proportion of patients achieving sustained clinical remission, not survival or progression outcomes with time-to-event analysis).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients. PMID 40419286 · Br J Haematol · 2026-Jan The publication is a comparative study of external versus internal control arms for a randomized trial, not the primary formal result report of the randomized Phase III trial. The trial phase is not explicitly stated in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systemic Inflammatory Markers Correlate with Chronic Kidney Disease-Associated Pruritus and Response to Treatment. PMID 40409676 · J Invest Dermatol · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized clinical trial to assess the effectiveness of thermal ablation versus loop electrosurgical excision procedure for cervical cancer risk reduction in women living with HIV in Mozambique. PMID 40399211 · Int J Gynecol Cancer · 2026-Jan The record describes a protocol for a randomized trial comparing two procedural interventions (thermal ablation vs. LEEP) for cervical precancer in women with HIV. It is not a drug intervention, does not specify Phase III, does not include time-to-event efficacy endpoints (OS, PFS, etc.), and is not a results report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
PERMA-based psychological intervention in glioma rehabilitation: An RCT examining affective distress, treatment adherence, and neuro-oncological outcomes. PMID 40340528 · Int J Psychiatry Med · 2026-Jan The study is a randomized trial in oncology with a time-to-event endpoint (Kaplan-Meier), but the intervention is a psychological intervention (PERMA-based), not a drug-containing intervention. Therefore, it does not meet the inclusion criteria requiring a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study. PMID 40338768 · JACC Heart Fail · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial. PMID 40208137 · JACC Heart Fail · 2026-Jan 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016-2026): A Decade in Review. PMID 41892168 · Curr Oncol · 2026-Feb-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in China. PMID 41810101 · J Clin Transl Hepatol · 2026-Feb-28 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Postoperative intravenous lidocaine infusion for pain management in pelvic bone tumor surgery patients: a randomized, double-blind, controlled trial. PMID 41764583 · J Anesth Analg Crit Care · 2026-Feb-28 The study is a randomized, double-blind, controlled trial in oncology patients (pelvic bone tumor surgery). However, it is excluded because the primary outcome is postoperative opioid consumption and other safety/efficacy metrics, not a time-to-event endpoint (e.g., OS, PFS, DFS). The intervention (lidocaine) is for perioperative pain management, not a systemic oncology drug intervention. The phase is not specified, but this does not affect eligibility as the key missing criterion is the endpoint type.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Equine-assisted Biographical Work (EABW) in older adults with subclinical depression: a randomized controlled trial. PMID 41761195 · BMC Complement Med Ther · 2026-Feb-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Feasibility and preliminary efficacy of an art-making program to manage fear of cancer recurrence (AM-I-FCR) in lung cancer patients: a randomized controlled pilot study. PMID 41761252 · BMC Med · 2026-Feb-27 The study is a randomized, human, oncology trial, but it is excluded because it is not Phase III/IIIb or Phase II/III (it is a pilot study), lacks a drug-containing intervention, and does not have a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intranasal low-dose dexmedetomidine alleviates propofol-associated postoperative sleep disturbance in female hysteroscopy patients: a randomized controlled trial. PMID 41761098 · BMC Anesthesiol · 2026-Feb-27 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study. PMID 41761058 · J Headache Pain · 2026-Feb-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. PMID 41760643 · Nat Commun · 2026-Feb-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Once-Weekly Lonapegsomatropin Was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial. PMID 41758754 · Horm Res Paediatr · 2026-Feb-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy. PMID 41760424 · Eur Urol Focus · 2026-Feb-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Double-blind, Placebo-controlled Trial of Adipose-derived Regenerative Cells Injected into Corpora Cavernosum Following Radical Prostatectomy. PMID 41760422 · Eur Urol Focus · 2026-Feb-26 The study is an oncology-related (post-radical prostatectomy) randomized trial with original results, but it does not meet all inclusion criteria. The intervention is a cell therapy (ADRCs), not a drug. There is no time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.); the primary endpoint is a change in erectile function score. The trial phase is not explicitly stated, preventing confirmation of it being a definitive Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prophylactic LYMphatic Reconstruction (LYMbR) to prevent lymphedema after node dissection for cutaneous malignancies: a randomized controlled trial. PMID 41749241 · Trials · 2026-Feb-26 The record describes a Phase III randomized controlled trial protocol for a surgical intervention (prophylactic lymphatic reconstruction) to prevent lymphedema after node dissection for cutaneous malignancies. While it is oncology-related, human, randomized, and Phase III, it is a protocol without results and does not report a time-to-event efficacy endpoint. The intervention is non-drug, and no primary efficacy endpoint for time-to-event (e.g., overall survival, progression-free survival) is specified.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. PMID 41749205 · BMC Med · 2026-Feb-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial. PMID 41748622 · Nat Commun · 2026-Feb-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for ARPI-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer: a pooled analysis of KEYNOTE-921 and CheckMate 7DX trials. PMID 41741934 · Int Urol Nephrol · 2026-Feb-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of tumor treating fields on overall and progression-free survival in newly diagnosed glioblastoma: A systematic review and meta-analysis. PMID 41741710 · Neurosurg Rev · 2026-Feb-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tecovirimat for the Treatment of Mpox. PMID 41740032 · N Engl J Med · 2026-Feb-26 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Frailty, comorbidity and survival comparisons between populations eligible for screening according to risk factor versus risk score criteria: results from the Yorkshire Lung Screening Trial. PMID 41593003 · Thorax · 2026-Feb-26 The record describes a randomized trial of lung cancer screening criteria, but the intervention is a screening program (non-drug), and the trial phase is not specified as Phase III/IIIb or Phase II/III. It does not meet all required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evidentiary Standards for Newly Approved Antibiotics for Uncomplicated Urinary Tract Infections. PMID 41892400 · Antibiotics (Basel) · 2026-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial. PMID 41742206 · BMC Med · 2026-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Digital Attention Bias in Cancer Survivors Intervention for Adolescent and Young Adult Cancer Survivors: Protocol for a Pilot Randomized Controlled Trial. PMID 41740148 · JMIR Res Protoc · 2026-Feb-25 The record is a protocol for a pilot randomized trial evaluating a digital psychosocial intervention (not a drug) in adolescent and young adult cancer survivors. It lacks results, is not Phase III, and has no time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term efficacy of ursodeoxycholic acid for the prevention of gallstone formation after gastrectomy in patients with gastric cancer: a randomized clinical trial. PMID 41738624 · Int J Surg · 2026-Feb-25 While the study is a randomized, double-blind, placebo-controlled trial in human gastric cancer patients with a time-to-event endpoint, it evaluates prevention of a post-surgical complication (gallstone formation) rather than an oncology efficacy endpoint like survival or tumor progression. Therefore, it does not meet the cohort's criteria for including trials with a primary or key secondary time-to-event efficacy endpoint for malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). PMID 41576645 · Eur J Cancer · 2026-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients. PMID 41321121 · Clin Infect Dis · 2026-Feb-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant. PMID 41321117 · Clin Infect Dis · 2026-Feb-25 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8. PMID 41208546 · Clin Infect Dis · 2026-Feb-25 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. PMID 40874769 · Clin Infect Dis · 2026-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -